Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
GLP-1 receptors: Slow digestion and reduce appetite.
GIP receptors: Improve insulin release and blood sugar management.
Glucagon receptors: Increase energy expenditure and help the body burn more calories at rest.
Recent data published in The New England Journal of Medicine highlights the significant potential of this compound. In clinical settings, Retatrutide has demonstrated:
Significant Weight Reduction: Study participants observed a 22% to 24% reduction in total body weight over a 48-week period.
Extended Results: Ongoing research suggests potential weight loss of up to 28% over 68 weeks at optimal dosages.
Metabolic Support: Beyond weight loss, the compound is being evaluated for its ability to regulate blood sugar and improve overall metabolic markers.
Format: Weekly subcutaneous injection.
Safety Profile: Observed effects are consistent with the incretin class, including manageable gastrointestinal transitions such as nausea or mild digestive changes.
Regulatory Status: Please note that as of early 2026, Retatrutide remains an investigational compound. It is undergoing rigorous Phase 3 testing and has not yet received final approval from the FDA or MHRA for general prescription use.
Important Research Notice: Retatrutide is currently intended for clinical trial and laboratory research purposes only. It is vital to source all metabolic compounds from verified, high-quality providers to ensure purity and safety
GLP-1 receptors: Slow digestion and reduce appetite.
GIP receptors: Improve insulin release and blood sugar management.
Glucagon receptors: Increase energy expenditure and help the body burn more calories at rest.
Recent data published in The New England Journal of Medicine highlights the significant potential of this compound. In clinical settings, Retatrutide has demonstrated:
Significant Weight Reduction: Study participants observed a 22% to 24% reduction in total body weight over a 48-week period.
Extended Results: Ongoing research suggests potential weight loss of up to 28% over 68 weeks at optimal dosages.
Metabolic Support: Beyond weight loss, the compound is being evaluated for its ability to regulate blood sugar and improve overall metabolic markers.
Format: Weekly subcutaneous injection.
Safety Profile: Observed effects are consistent with the incretin class, including manageable gastrointestinal transitions such as nausea or mild digestive changes.
Regulatory Status: Please note that as of early 2026, Retatrutide remains an investigational compound. It is undergoing rigorous Phase 3 testing and has not yet received final approval from the FDA or MHRA for general prescription use.
Important Research Notice: Retatrutide is currently intended for clinical trial and laboratory research purposes only. It is vital to source all metabolic compounds from verified, high-quality providers to ensure purity and safety
